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Introduction: Praziquantel (PZQ) is the only commercially available drug for 
schistosomiasis. The current shortage of alternative effective drugs and the lack of 
successful preventive measures enhance its value. The increase in the prevalence of 
PZQ resistance under sustained drug pressure is, therefore, an upcoming issue. 
Objectives: To overcome the tolerance to PZQ using nanotechnology after laboratory 
induction of a Schistosoma mansoni (S. mansoni) isolate with reduced sensitivity to the 
drug during the intramolluscan phase.  
Materials and methods: Shedding snails were treated with PZQ doses of 200 mg/kg 
twice/week, followed by an interval of one week, and then repeated twice in the same 
manner. The success of inducing reduced sensitivity was confirmed in vitro via the 
reduction of cercarial response to PZQ regarding their swimming activity and death 
percentage at different examination times. 
Results: Oral treatment with a single PZQ dose of 500 mg/kg in mice infected with 
cercariae with reduced sensitivity to PZQ revealed a non-significant reduction (35.1%) 
of total worm burden compared to non-treated control mice. Orally inoculated PZQ-
encapsulated niosomes against S. mansoni with reduced sensitivity to PZQ 
successfully regained the pathogen’s sensitivity to PZQ, as evidenced by measuring 
different parameters in comparison to the non-treated infected animals with parasites 
with reduced sensitivity to PZQ. The mean total worm load was 1.33 ± 0.52 with a 
statistically significant reduction of 94.09% and complete eradication of male worms. A 
remarkable increase in the percentage reduction of tissue egg counts in the liver and 
intestine (97.68% and 98.56% respectively) was obtained associated with a massive 
increase in dead eggs and complete absence of immature stages. 
Conclusion: PZQ-encapsulated niosomes restored the drug sensitivity against laboratory-
induced S. mansoni adult worms with reduced sensitivity to PZQ. 
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Introducción. El praziquantel (PZQ) es el único fármaco disponible comercialmente 
para la esquistosomiasis. La escasez actual de medicamentos alternativos eficaces y 
la falta de medidas preventivas eficaces aumentan su valor. El aumento de la 
prevalencia de la resistencia al PZQ bajo una presión prolongada del fármaco es, por 
tanto, un tema emergente. 
Objetivos. Superar la tolerancia a PZQ mediante nanotecnología después de la 
inducción en laboratorio de un aislamiento de Schistosoma mansoni (S. mansoni) con 
sensibilidad reducida al fármaco durante la fase intramolusca. 
Material y métodos. Los caracoles que liberaban cercarias se trataron con dosis de 
PZQ de 200 mg / kg dos veces por semana, seguido de un intervalo de una semana, y 
luego se repitieron dos veces de la misma manera. El éxito de inducir una sensibilidad 
reducida se confirmó in vitro mediante la reducción de la respuesta de las cercarias al 
PZQ con respecto a su actividad de natación y el porcentaje de muerte en diferentes 
momentos de examen. 
Resultados. El tratamiento oral con una dosis única de PZQ de 500 mg / kg en 
ratones infectados con cercarias con sensibilidad reducida a PZQ reveló una 
reducción no significativa (35,1%) de la carga total de gusanos en comparación con 
los ratones de control no tratados. Los niosomas encapsulados en PZQ inoculados por 
vía oral contra S. mansoni con sensibilidad reducida a PZQ permitieron reestablecer 
con éxito la sensibilidad del patógeno a PZQ, como lo demuestra la medición de 
diferentes parámetros en comparación con los animales infectados no tratados con 
parásitos con sensibilidad reducida a PZQ. La carga media total de gusanos fue de 
1,33 ± 0,52 con una reducción estadísticamente significativa del 94,09% y la 
erradicación completa de los gusanos machos adultos. Se obtuvo un aumento notable 
en el porcentaje de reducción del recuento de huevos en tejido en el hígado y el 
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intestino (97,68% y 98,56% respectivamente) asociado con un aumento masivo de 
huevos muertos y ausencia total de estadios inmaduros. 
Conclusión. Los niosomas encapsulados en PZQ restauraron la sensibilidad al 
fármaco contra gusanos adultos de S. mansoni inducidos en laboratorio con 
sensibilidad reducida a PZQ. 






















Schistosomiasis is a major health problem in tropical and sub-tropical areas. The 
global health burden of schistosomiasis is estimated at 3.3 million disability-adjusted 
life years (DALYs), a value similar to that of malaria and tuberculosis (1). 
Chemotherapy remains the primary intervention for such a disease (2), and since 
praziquantel (PZQ) is essentially the only drug currently available (3), such a reliance 
on a single drug for a disease of this magnitude represents a precarious situation, 
particularly in light of reports concerning schistosome isolates having reduced 
susceptibility to PZQ in the field (4,5). 
Drug resistance depends on the selective pressure of drug exposure (6). Unfortunately, 
the mechanism of action of PZQ is not yet completely understood (7). Therefore, the 
mechanism of PZQ tolerance and the methods for overcoming this issue remain 
unclear. Ways to overcome such a knowledge shortage include generation of 
laboratory-induced schistosome isolates with reduced sensitivity to PZQ to permit 
comparison between them and susceptible parasites. Under laboratory conditions, 
induction of resistance has been achieved via two approaches in either the definitive or 
intermediate hosts. In the first approach, mice infected with Schistosoma mansoni (S. 
mansoni) were initially treated with sub-curative doses of PZQ followed by increasing 
the dose in animals for several passages in mice/snails to complete the parasite’s life 
cycle (8,9). Alternatively, the second approach involves selecting PZQ-resistant 
parasites during the asexual stages of the life cycle of the snail intermediate host 
(10,11). An important mechanism regarding PZQ resistance involves an increase in PZQ 
efflux by the multidrug resistance (MDR) transporters, in which the glycoprotein 
transporters such as SmMDR2 and multidrug resistance-like proteins (SmMRP1) are 
implied to be important (12). 
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Many strategies, including nanotechnology, have been adopted to increase the 
effectiveness of the drugs (13). Lipid-based nanoparticles, including liposomes, solid 
lipid nanoparticles and nanostructured lipid carriers (the second generation of solid lipid 
nanoparticles), present promising oral drug-delivery candidates for PZQ (14-16). 
Furthermore, to circumvent MDR, nanotechnology provides an innovative and 
promising alternative to conventional chemotherapeutics. Successful examples of 
nanotechnology use in reversing drug resistance and regaining drug activity include 
studies conducted utilizing antibiotics (17,18), anticancer drugs (19) and antimalarial 
drugs (20). Recently, the co-delivery of chemotherapeutics and inhibitors of multidrug 
resistance transporters using lipid-based nanocarriers provided a promising approach 
for overcoming drug resistance and reducing the potential toxicity of chemotherapeutic 
drugs in different diseases (21). Niosomes are among the best lipid carriers. They are 
widely used as alternatives to liposomes and are even preferred over liposomes due to 
their high chemical stability and low cost. Moreover, niosomes possess other 
characteristics that make them promising candidates for clinical use (22). They improve 
the oral bioavailability of drugs, enhance their dissolution rate and protect them from 
being prematurely degraded/inactivated in addition to their known low toxicity and non-
immunogenicity (23). Niosomes are essentially composed of cholesterol and non-ionic 
surfactant vesicles, in which they trap and retain the aqueous solution of the solute 
particles. In addition, various ionic amphiphiles are incorporated into their structure to 
achieve stability by inducing negative or positive charges (24). This unique structure of 
niosomes allows for the incorporation of hydrophilic drugs into its aqueous core and 
lipophilic drugs into its membrane bilayer (25). Thus, they were selected in the current 
work as a carrier system for overcoming reduced sensitivity to PZQ, primarily due to 
their unique character of surfactant inclusion which sensitizes resistant cells and 
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inhibits glycoprotein efflux transporters (26). This may aid in expanding the spectrum of 
niosome-loaded drugs in treating resistant organisms in the future. Therefore, in the 
present work, the laboratory induction of reduced sensitivity to PZQ in the S. mansoni 
asexual life cycle stages inside a Biomphalaria alexandrina snail host was performed; 
in view of the niosomes’ potential as drug susceptibility enhancers, the effect of PZQ-
loaded niosomes in mice infected with S. mansoni isolate with reduced sensitivity to 
PZQ was evaluated. 
Material and methods  
A brief summary of the methodology carried on in this work was presented in figure 1. 
Animals and parasites 
An Egyptian strain of S. mansoni was used in all experiments. Ten Swiss strain albino 
mice, aged 4-6 weeks and weighing 20-30 g, previously infected with S. mansoni were 
purchased from the Schistosome Biologic Supply Programme (SBSP), Theodor Bilharz 
Institute (TBI), Giza, Egypt.  
In this study, work involving laboratory animals was conducted in accordance with the 
Egyptian National Animal Welfare Standards and was approved by the Ethics 
Committee of the Faculty of Medicine, Alexandria University, Egypt (protocol approval 
number: 020732). 
Maintenance of the S. mansoni life cycle was conducted among laboratory snails and 
inbred Swiss albino mice raised and maintained at the Animal Unit, Department of 
Medical Parasitology, Faculty of Medicine, Alexandria University, Egypt. At seven 
weeks post infection (p.i.), the mice were administered intraperitoneal cal-heparin 
(5000 I.U/ ml; 0.1 ml each) and were euthanized by ether; their livers were used as a 




Snail source, maintenance and infection 
Four hundred laboratory-bred susceptible Biomphalaria alexandrina snails were 
supplied by SBSP/TBRI, Giza, Egypt, and were used for inducing PZQ reduced 
sensitivity during the intra-molluscan phase to harvest cercariae for the in vitro study 
and animal infection. Snails were maintained in the Department of Medical 
Parasitology laboratory, Faculty of Medicine, Alexandria University, Egypt, in 
transparent plastic aquaria; each contained 50 snails and was maintained at 26-28°C 
inside an incubator. Each container contained five liters of well-aerated aged 
dechlorinated tap water (DTW) that was replaced twice a week. Freshly washed lettuce 
leaves were supplied as snail food every couple of days, and soft chalk was added to 
all aquaria. Dead snails were regularly removed. Pieces of foam were placed inside the 
containers for egg deposition (28). 
At seven weeks post infection, the purchased mice were sacrificed, and their livers became 
the source of parasite eggs for snail infection. The collected eggs were exposed to light to 
stimulate miracidial release. The snails were individually exposed to 8-10 vigorously 
swimming, freshly hatched miracidia in direct sunlight for 3-4 hours. Afterwards, the snails 
were kept in the dark and maintained under the conditions previously described (29). 
Induction of reduced sensitivity to PZQ in the intra-molluscan phase  
Preparation and administration of the drug 
To induce reduction in sensitivity to PZQ, 100 g of 99.5% pure PZQ white powder, 
C19H24N2O2, of molecular weight 312.40606 g/mol was kindly provided by Alexandria 
Company for Pharmaceuticals & Chemical Industries, Egypt. The drug was 
incorporated into mouse chow (purchased from the local market) (11). The chow was 
ground up with calcium carbonate in a 9:1 ratio. The ratio was reconstituted with water 
until it became pasty. The snails were individually weighed to calculate the drug 
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dosage for each snail. PZQ was administered in doses of 200 mg/kg twice/week, 
followed by an interval of one week, and then repeated twice in the same manner (30). 
The PZQ dose to be administered per kg was incorporated into 100 mg of food (the 
amount of food administered for each snail).  The amount of food provided each day 
was allowed to be totally ingested by each snail, suggesting that the snails received the 
entirety of the drugs offered in the ration (10). 
The snails infected with S. mansoni were checked for cercarial shedding four weeks 
after infection. Two hundred shedding snails were divided equally into two groups. 
Group A contained the infected PZQ-unexposed snails used as a source of PZQ-
susceptible cercariae.Group B contained the infected PZQ-exposed snails. Both snail 
groups were maintained in glass containers and DTW was changed every 24 hours.  
Cercarial harvest 
Biomphalaria alexandrina snails, infected with the Egyptian strain of S. mansoni in 
each group, were used for cercarial harvest to check the cercarial response to PZQ in 
vitro and for evaluating the efficacy of PZQ against adult S. mansoni with reduced 
sensitivity to PZQ in animal models using nanotechnology. Each snail was placed in a 
200 ml beaker containing dechlorinated tap water (DTW) at 30°C and was kept under 
intense illumination at a distance of 50 cm from the light source. After two hours, 
cercarial suspension was collected. Only 50 µl of the cercarial suspension were stained 
by Lugol’s iodine to facilitate cercarial count under a stereo microscope while the 
remaining cercarial suspension was used to complete the study (31). 
Confirmatory test for cercarial response to PZQ 
A stock solution of 0.1% dimethyl sulfoxide (DMSO) in distilled water was used as a 
drug solvent and a control. Solutions of 5x10-6 M PZQ in 0.1 % DMSO were prepared 
and stored for a maximum of two weeks in the refrigerator. The assay was performed 
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using ordinary glass slides without using a cover slip. Three sets of slides were used 
for each group. For each set, the number of cercariae was 5–7 in 20 μl of DTW per 
drop, two drops per slide (36 S. mansoni cercariae). The first set of cercariae received 
no drug, the second received 20 μl of 0.1% DMSO per drop and the third received 20 
μl of the PZQ solution per drop. Cercariae were examined under an ordinary 
microscope every ten minutes for one hour. They were carefully observed and 
classified as unaffected, affected or dead. 
To avoid the slides drying up and the resulting increase in the PZQ concentration, and 
to stabilize the temperature during the 60-minute examination period, the slides were 
kept in a plastic box on a thin (3 mm), wet sponge. The temperature of the sponge was 
adjusted to 28oC by adding warm water (32). This study was performed in triplicate.  
Efficacy of PZQ on adult S. mansoni with reduced sensitivity to PZQ using 
nanotechnology 
Drug preparation 
PZQ suspension  
500 mg of PZQ powder was dissolved in one ml 60% ethanol and then suspended in a 
phosphate buffer saline (7 ml) to create a total volume of 8 ml. Each mouse was 
administered a single dose of PZQ (500 mg/kg) as 0.2 ml PZQ suspension (33).  
Preparation and characterization of PZQ-encapsulated niosomes: 
Preparation of niosomes 
Niosomes were prepared via the thin film hydration method; Span 60 and cholesterol in 
a 7:6 molar ratio were dissolved in 10 ml of chloroform and ethanol mixture (7/3, v/v), as 
an organic solvent, in a round-bottom flask of a rotator evaporator. Extracting the solvent 
from the nanodroplets was achieved via evaporation at 55°C in the rotator evaporator 
under reduced pressure (200 mmHg) for 15 minutes until a thin film was created in the 
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inner wall of the flask, leading to the formation of nanoparticles by precipitating 
macromolecules. The dry lipid film was hydrated with 10 ml PBS (pH 7.4), shaken for 15 
minutes at low speed at 55 °C and hand shaken for 15 minutes at room temperature to 
obtain a lipid suspension. The particles were then downsized by sonication via a bath-type 
sonicator operated at a frequency of 55 KHz (kilo Hertz) for 5–10 minutes at 42°C (the 
transition temperature of the lipid) (34).  
Preparation of PZQ-encapsulated niosomes 
The same method of niosomes preparation was followed in preparing PZQ-
encapsulated niosomes with the addition of 500 mg of PZQ to Span 60 and cholesterol 
in the first step.  
Lyophilization of PZQ-encapsulated niosomes 
PZQ-niosomes solutions were placed in 50 ml tubes, frozen in liquid nitrogen and 
freeze-dried using a vacuum freeze-drying machine at a pressure of 26.5 pascal. The 
lyophilized particles were then characterized (35). 
Characterization of PZQ-encapsulated niosomes 
Particle size analyzer 
Distributing the size of PZQ-encapsulated niosome particles was determined through 
laser light scattering on a Beckman coulter particle size analyzer. PZQ-encapsulated 
niosomes were added to the sample dispersion unit containing the stirrer and were 
stirred to reduce the aggregation between the PZQ-encapsulated niosomes while the 
laser obscuration range was maintained at 15–20%. The mean particle size was 
measured after performing the experiment in triplicate (36). 
Transmission electron microscopy (TEM) 
The physical size and shape of the prepared PZQ-encapsulated niosomes were 
determined using a transmission electron microscope. For this purpose, the particle 
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suspension was diluted 10 times with distilled water and deposited dropwise onto a 
400-mesh copper grid coated with carbon film and were allowed to dry in the air before 
being examined under the microscope (37).  
Zeta potential 
The zeta potential (a key indicator of colloidal dispersion stability) of PZQ-encapsulated 
niosomes dispersed in phosphate buffer solution (pH 6.5) was determined via laser 
Doppler anemometry. The nanovesicle suspension was diluted to 4 ml with a phosphate 
buffer (pH 6.5). An electric field of 150 millivolts (mV) was applied to observe the 
electrophoretic velocity of the vesicles. All measurements were made at 25 ºC in triplicate 
at the same ionic concentration (35). 
Determination of encapsulation efficiency of niosomes 
The encapsulation efficiency (EE) of PZQ was expressed as a ratio between the PZQ 
concentration in the niosomes and the concentration of PZQ added to the system. The 
amount of PZQ in the niosomes was determined by recording the absorbance of the loading 
solution at λmax= 490 nm (after removing niosomes by centrifugation at 10,000 rpm for 30 
minutes). The unloaded PZQ in the supernatant was determined using a spectrophotometer 
at λmax 490 nm. The EE of niosomes was calculated according to the following equation: EE 
= [(Dt-Du)/Dt] x 100, where Dt represents the total amount of drug and Du represents the 
amount of free drug (38). 
Experimental design 
One hundred and sixty laboratory-bred Swiss strain albino mice aged 4-6 weeks and 
weighing 20-30 g were individually infected with 100 cercariae using the paddling tail-
immersion technique based on the method described by Smithers and Terry (39). The 
mice were divided equally into two main groups: Group I: Mice were infected with S. 
mansoni susceptible cercariae from PZQ-unexposed snails (group A) and Group II: 
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mice were infected with S. mansoni cercariae with reduced sensitivity to PZQ from 
PZQ-exposed snails (group B). Each group was further subdivided equally into four 
main subgroups: Subgroup a: infected non-treated mice; Subgroup b: infected PZQ-
treated mice, in which each animal was inoculated with a single oral dose of 500 mg/kg 
(in two divided doses on the same day); Subgroup c: infected niosomes-treated mice; 
and Subgroup d: infected PZQ-niosomes-nanoparticles-treated mice. Mice treated 
with niosomes or PZQ-encapsulated niosomes were inoculated orally with 400 µl single 
therapy of the prepared suspension divided into two doses on the same day. 
Drugs were administrated, against the adult S. mansoni stage, 42 days post infection. 
All mice were perfused from the hepatic and mesenteric vessels 49 days after cercarial 
challenge (39). The experiment was repeated thrice. Having the average replicate, the 
data from one of the independent experiments is presented.  
The following parameters were done for assessing drugs against PZQ-susceptible and 
S. mansoni adult isolates with reduced sensitivity to PZQ: 
Adults worm burden  
Recovered worms were counted and sexed under a stereo microscope. 
Tissue egg count  
Egg counts in both the liver and intestine were performed according to Cheever's 
technique (40). The mouse liver and intestine were digested by overnight incubation in 
4% (w/v) potassium hydroxide at 37°C. The digested tissue suspensions were 
thoroughly stirred, and eggs were counted in 2x50 µl samples on microscope slides 
under 10x magnification. The mean of the duplicate egg count was determined for 
each mouse. The treatment-induced percentage reductions in worm and egg burdens 
were calculated as P = (C-V/C) x100. 
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(Where P is the percentage of worm/egg counts reduction; C is the mean number of 
worms/eggs recovered from control mice; and V is the mean number of worms/eggs 
recovered from treated mice). 
Egg developmental stages (oogram pattern) 
Assessment of therapeutic efficacy is based on quantitative and qualitative oogram 
techniques following the criteria described by Pellegrino & Faria (41). After perfusion of 
the portal system, 5–10 cm of the middle portion of the small intestine was opened 
longitudinally with a pair of scissors and rinsed in a petri dish of saline solution, and 
three 10 mm fragments were cut off and processed for oogram. One hundred eggs 
were counted in each fragment and classified, according to the different stages of 
development, as immature, mature or dead. 
Statistical analysis 
The statistical package for social sciences (SPSS) software package version 20.0 
statistical programme was utilized for both data presentation and statistical analysis of 
the results. The descriptive measures used for the results were arithmetic mean, 
standard deviation (SD), minimum (Min.), maximum (Max.) and median. The level of 
significance selected for this study was p equal to or less than 0.05 (p ≤ 0.05). The 
Kolmogorov-Smirnov test was used to verify the normality of distribution. Kruskal Wallis 
test was used for abnormally distributed quantitative variables to compare between 
more than two studied groups, and Mann Whitney test for pairwise comparisons (42).  
Results 
In vitro cercarial response to PZQ  
The onset of the first cercarial re-shedding from PZQ-exposed snails occurred eight 
weeks after the cessation of drug exposure. The effect of PZQ on the harvested 
cercariae from the unexposed and exposed groups (group A and group B) was 
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observed and classified into three stages. Stage 1: the unaffected live cercariae 
demonstrating normal swimming activity (rapid linear progressive swimming). The 
cercariae exhibited body contractions during movement with or without coiling of rami 
of bifurcation (figures 2A and 2B). Stage 2: affected live cercariae demonstrating a: 
intermittent spins (cercariae remained momentarily motionless before the body and tail 
suddenly rotated around their central axis with no linear progressive movement); b: a 
tilted head (a cercaria weakly moving its head or tail without any progressive 
movement) (figure 2C); c: sluggish head movement with complete stoppage of body 
movement. A loss of body contractions occurred with or without coiling of rami of 
bifurcation (figures 2D and 2E). Stage 3: dead cercariae with complete stoppage of 
head and tail movement. Some cercariae exhibited separation of the tail (figure 2F). 
At the beginning of the experiment, the re-shed cercariae from PZQ-exposed snails in 
group B revealed no detectable differences regarding the cercarial activity compared 
with cercariae harvested from snails in group A (stage 1). Immediately after adding 
PZQ, an initial increase in the cercarial activity of snails in group B (prompt linear 
progressive and zigzag swimming motions) for approximately 20 seconds was 
observed. At the various examination points, statistically significant differences were 
recorded between cercariae harvested from both snail groups (group A and group B). 
After the first 10 minutes, 91.67% of cercariae from the group B snails were completely 
unaffected (stage 1) with no recorded cercarial deaths, while the remaining cercariae 
exhibited intermittent spins (stage 2). In contrast, after the same duration, 50.92% of 
cercariae from PZQ-unexposed snails (group A) died (stage 3). The cercarial death 
percentage in the same group increased up to 87.3% after 20 minutes of drug 
exposure, with total cercarial deaths occurring at the 30-minute examination point. On 
the other hand, by increasing the duration of drug exposure, the influence of PZQ on 
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the harvested cercariae from the PZQ-exposed group (group B) displayed slow and 
gradual enhancing effects.  
After 30 minutes, up to 65.75% of cercariae harvested from group B (PZQ-exposed 
snails) remained unaffected. The sum of the affected and dead cercariae markedly 
increased at the 50-minute and 60-minute examination points, reaching approximately 
80.55% at both points. At these examination points, complete death was achieved by 
33.33% and 54.64% of the cercariae, respectively (figure 3). 
Characterization of PZQ-encapsulated niosomes  
The TEM of the prepared niosomes and PZQ-encapsulated niosomes revealed 
spherical, smooth surface nanoparticles with average sizes of 69.9-120 nm (figure 4A) 
and 43.2-131 nm (figure 4B), respectively. The zeta potential of the niosomes was -
16.7 mV, while that of the PZQ-encapsulated niosomes was -20.2 mV. In addition, the 
particle size distribution performed by the particle size analyzer revealed the niosomes 
without PZQ to have a mean particle size of 83.55 nm and showed a polydispersity 
index of 0.715 (i.e. less than 1), indicating the homogeneous nature of the formulation. 
On the other hand, the particle size distribution of the PZQ-encapsulated niosomes 
revealed a mean particle size of 97.14 nm, and the polydispersity index was 0.534 (i.e. 
less than 1). 
The encapsulation efficiency of PZQ was expressed as the ratio of the PZQ concentration 
in the niosomes and the PZQ concentration added to the system. This formula produced a 
percentage of encapsulation efficiency of 66.8%. 
In vivo efficacy of PZQ and PZQ-encapsulated nanoparticles on adult S. mansoni  
Adults worm burden  
Recovered worms collected 49 days p.i. from all subgroups were counted and sexed 
under a dissecting microscope. A marked reduction of the drug potency was detected 
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against adults collected from PZQ-treated mice infected with cercariae with reduced 
sensitivity to PZQ (subgroup IIb) compared with its control (non-treated mice infected 
with cercariae with reduced sensitivity to PZQ (subgroup IIa), with a total worm 
reduction of 35.1%. This result was statistically non-significant  
(p > 0.05), whereas, under the same circumstances, the reduction of the female adult 
worm burden was statistically significant (47.37%; p ≤ 0.05) (table 1). 
No activity of niosome nanoparticles against the adult stage was detected in niosomes-
treated mice infected with cercariae either PZQ-susceptible or with reduced sensitivity 
to PZQ (subgroups Ic and IIc) compared with their controls (subgroups Ia and IIa). The 
percentage reductions were 2.69% and 5.78%, respectively that were statistically non-
significant (P > 0.05). Meanwhile, oral treatments with PZQ-encapsulated niosomes 
(subgroups Id and IId) revealed the highest drug efficacy among all the studied 
subgroups. Highly significant reductions were obtained by comparing subgroups Id and 
IId with their controls (subgroups Ia and IIa). The mean total worm load was 1.33 ± 
0.52 with a statistically significant reduction of 94.09%, and the complete elimination of 
adult male worms was detected in S. mansoni with reduced sensitivity to PZQ treated 
with PZQ-encapsulated niosomes (subgroup IId) (P ≤ 0.05). However, in subgroup Id 
(PZQ-susceptible S. mansoni treated with PZQ-encapsulated niosomes), a slight 
enhancement of the drug efficacy was reported with a statistically significant reduction 
of 95% (p ≤ 0.05).  
Tissue egg count and oogram patterns  
Niosomes-treated mice infected with PZQ-susceptible cercariae or cercariae with 
reduced sensitivity to PZQ, (subgroups Ic and IIc, respectively), did not reveal 
statistically significant differences in each total egg count in liver and intestinal tissues 
and their oogram patterns (p ˃ 0.05). However, oral treatment with PZQ or PZQ-
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encapsulated niosomes in either the mice infected with PZQ-susceptible cercariae 
(subgroups Ib and Id) or the mice infected with cercariae with reduced sensitivity to PZQ 
(subgroups IIb and IId) demonstrated statistically significant reductions in the egg counts in 
both hepatic and intestinal tissues compared with those of their control subgroups (p ≤ 
0.05) (table 2). 
For the PZQ-susceptible isolate, PZQ and PZQ-encapsulated niosomes-treated mice 
(subgroups Ib and Id) revealed a statistically significant increase in the dead eggs, with 
mean percentages of 47.67% and 69.90%, respectively, and a statistically significant 
reduction in the immature eggs, with mean percentages of 11.83% and 8.95%, 
respectively (P ≤ 0.05) (table 3).  
On the other hand, mice infected with less sensitive cercariae to PZQ, orally treated 
with PZQ (subgroup IIb), exhibited a much lower reduction in the number of immature 
eggs or an increase in the number of dead eggs. No significant changes in the 
percentage of the mature eggs were detected in subgroup IIb compared with subgroup 
IIa (p > 0.05). However, a remarkable increase in the percentage of dead eggs was 
detected in subgroup IId, in which the animals received PZQ-encapsulated niosomes, with 
a mean percentage of 87.67% ± 16.93.  
Discussion 
In the present work, schistosomes with reduced sensitivity to PZQ were obtained by 
drug selection during the asexual stages of the parasite in the snails. Shedding snails 
were treated with PZQ doses of 200 mg/kg twice/week, followed by an interval of one 
week, and then repeated twice in the same manner and reared in glass containers with 
changing the DTW every 24 hours. This approach is far less expensive, time 
consuming and labour intensive than other strategies applying drug pressure through 
multiple intra-mammalian stage passages (10). This regimen and rearing conditions 
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decreased the stress to which the snails were exposed, by dividing the dose of the drug 
and decreased time for the protein content of the paste in water to be fermented especially 
in a warm climate. Additionally, glass containers might offer a suitable temperature for snail 
growth and survival. Glass, for instance, is a very good insulator at room temperature, but 
becomes a conductor only when heated to a very high temperature. It is worthy to mention 
that, the approximate temperature for snail breeding and reproduction is 15 to 25 °C; snails 
cannot survive at > 29 °C, and may die within several hours at > 40 °C (43). 
PZQ-exposed snails demonstrated cessation of cercarial shedding for eight weeks 
after the termination of drug exposure. This finding can be partially explained according 
to Mattos et al. (44), who reported that a sublethal dose of PZQ induces morphological 
and metabolic alteration on the sporocysts, thereby interrupting the shedding. As the 
effect of PZQ on the sporocysts is temporary and reversible (33), re-shedding of the 
cercariae occurred after recovery.  
The success of inducing reduced sensitivity to PZQ in the present study was confirmed 
in vitro by reducing the PZQ susceptibility of cercariae harvested from the PZQ-
exposed snails compared with those from the PZQ-unexposed snails. Similarly, 
cercariae from snails infected by resistant isolates induced either experimentally or 
from the field exhibited reduced susceptibility to PZQ (32,45). Furthermore, the 
development of reduced sensitivity to PZQ was confirmed experimentally. The 
therapeutic efficacy of 500 mg/kg PZQ was greatly diminished such that the 35.1% 
reduction in the total worm load in treated mice infected with cercariae with reduced 
sensitivity to PZQ (subgroup IIb) was not significant compared with its control. 
According to Coles and Kinoti (46), this value for worm recovery is sufficient to provide 
an isolate resistant to PZQ. 
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Parasite and/or host factors could serve as underlying reasons for such 
unresponsiveness. In schistosomes, PZQ tolerance has been linked to over-expression 
of sarco/endoplasmic reticulum Ca 2+ ATPases, heat shock protein 70 in addition to 
glycoproteins or other multidrug transporters which lead to increase drug efflux 
(13,47,48). In an investigation on the possible host factors involved in the PZQ 
unresponsiveness, Hanallah et al. (49), reported that, PZQ insusceptible S. mansoni 
isolates possesses a different immunogenic makeup, both qualitatively and/or 
quantitatively when compared to isolates susceptible to PZQ. Furthermore, according 
to Botros et al. (50), the decreased sensitivity to PZQ could be due to a lower inhibition 
of hepatic drug-metabolizing enzymes, mainly cytochrome P 450 (CYP 450) in host 
infected with resistant schistosoma isolates with a consequently higher metabolic 
transformation of PZQ and lower level of serum drug concentration. Inhibition of 
activities of hepatic drug metabolizing enzymes in PZQ susceptible S. mansoni 
infected mice was previously reported (51). Such inhibition was attributed to possible 
denaturation of CYP 450 to its inactive form (CYP 422) as a result of the inflammatory 
reaction following egg deposition (52). Therefore, lower inhibition of such enzyme could 
occur in association with the demonstrated significant reduction of the hepatic egg 
counts in S. mansoni resistant isolate. 
When mice infected with S. mansoni isolate with reduced sensitivity to PZQ were 
treated with PZQ, a significant reduction in the female worm load in subgroup IIb 
compared with its control was demonstrated. The sex-specific sensitivity between male 
and female schistosomes could be explained by the fact that female schistosomes are 
more metabolically active than males. Interestingly, Kasinathan et al. (12) revealed an 
expression of higher levels of S. mansoni multidrug resistance-like protein transporters 
in males than in female worms that is responsible for resistance. This can 
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consequently explain the significant egg count reduction in the livers and intestines in 
mice infected with S. mansoni isolate with reduced sensitivity to PZQ and treated with 
PZQ (subgroup IIb) despite the non-significant reduction in the total worm load 
compared with their control (subgroup IIa). 
We reported the lack of any significant therapeutic effect of niosomes nanoparticles 
(NPs) orally administrated alone against adult S. mansoni with reduced sensitivity to 
PZQ. In contrast to metals, metal oxides and polymer-based NPs (which are well 
known for their highly potent antimicrobial effect), biological nanoparticles such as 
lipids are used only for drug delivery (13,18,53).  
Regarding niosomes´ safety, it is generally believed that lipids are biocompatible. A 
niosome is a non-ionic surfactant-based liposome. They are formed mainly by 
cholesterol incorporation as an excipient. In this study, Span 60 was the non-ionic 
surfactant used for preparing the niosomes particles. Span 60 is one of the alkyl esters, 
which are considered non-toxic and non-irritant materials (54). The Food and Drug 
Administration revised them in 2015 to be one of the food additives (55). These 
biophysical properties of niosomes support their tissue non-toxicity. 
Oral administration of niosomes in conjugation with PZQ against susceptible adult S. 
mansoni (subgroup Id) enhanced the therapeutic efficacy of the drug regarding the 
studied parasitological parameters. Due to the presence of hydrophilic, amphiphilic and 
lipophilic moieties in their structure, drug molecules with a wide range of solubility can 
be accommodated. These moieties may act as a depot, releasing the drug in a 
controlled manner. Similarly, solid lipid nanoparticles loaded with PZQ was effective in 
reducing the worm load and the tissue egg count (56). In this work, niosomes were 
able to promote a high concentration of the drugs in the target cells, and when 
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combined with sodium stibogluconate, they were found to be more effective than 
liposomes against experimental murine visceral leishmaniasis (57). 
The low aqueous solubility of PZQ is considered a limiting factor regarding its 
bioavailability (58). On the other hand, niosomal drug delivery enhances drug 
bioavailability by crossing the anatomical barrier of the gastrointestinal tract via cell 
transcytosis of Peyer's patches in the intestinal lymphatic tissues (23).  
In the present work, the regimen using single therapy of PZQ-encapsulated niosome in 
mice infected with cercariae with reduced sensitivity to PZQ was shown to be capable 
of successfully overcoming the tolerance of S. mansoni to PZQ, as revealed by our 
results displaying statistically significant reductions in all the evaluated indicators of 
drug susceptibility compared with all the relevant studied subgroups. Kulsirirat et al. 
(26) demonstrated that non-ionic surfactant had an inhibitory effect on P-gp ATPase 
activity transporters, which have been linked to PZQ resistance in schistosomes (12). 
This finding identified a possible mechanism by which niosomes could overcome the 
reduced sensitivity to PZQ. In agreement with the reported data, the development of 
new therapeutics or compounds that target these transporters proved useful in 
enhancing the efficacy of the drugs (6,59). Verapamil and Tariquidar are considered P-
gp inhibitors and can enhance the cytotoxic effects of chemotherapeutic drugs against 
resistant parasites (6,60). Moreover, a combination of the P-gp transporter inhibitors 
and PZQ has been successfully used against resistant S. mansoni (9,59).  
In the current study, we report that PZQ-encapsulated niosomes enhanced and restored 
drug sensitivity against susceptible and laboratory-induced S. mansoni adult worms with 
reduced sensitivity to PZQ, respectively. Interestingly, the primary mechanism of 
overcoming the drug resistance could be related to the surfactant inhibitory effect on P-gp 
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efflux transporters. Further investigations are necessary to verify the exact mechanisms by 
which niosomal nanoparticles exert their effect against tolerant parasites.  
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Fig. 2 In vitro cercarial response to PZQ (x100) (scale bar 100μ). Cercariae harvested  
from group B snails showing; (A): tail constrictions (arrow) with two coiled rami of the 
bifurcation; (B): cercariae showing tail constrictions (arrows) with no coiling of the 
ramus of the bifurcation; (C): cercariae showed tilting of the head (stage 3); (D): 
cercariae showing disappearance of tail constrictions (stage 4) with two rami of the 
bifurcation coiled; (E): cercariae showing disappearance of tail constrictions (stage 4) 
with no coiling of ramus of the bifurcation; (F): dead cercariae showing separation of 





Fig. 3 In vitro effect of 5x10-6 M PZQ on the cercariae (n= 36) harvested from (A): PZQ 
unexposed control group (group A) and (B): PZQ exposed (group B) snails at a dose of 
200 mg/kg PZQ twice/week followed by an interval of one week, and then repeated 
twice in the same manner. Lines represent mean count of un-affected, affected and 
dead cercariae after drug exposure every ten minutes for one hour. Error bars 





Fig. 4 Transmission electron microscope of the nanoparticles: (A): rounded smooth 
surface of free niosomes with average size of 69.9- 120 nm (5000X); (B): PZQ 
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p7= 0.092, p8<0.001*, p9= 0.004*, p10=0.645 
% 
Reduction 
 ↓90.27 ↓2.69 ↓95.0  ↓35.1 ↓5.78 ↓94.09 
Female 
worm load 
        






















p1= 0.003*, p2=0.254, 
p3<0.001* 
 




p7= 0.255, p8= 0.190, p9= 0.170, p10=0.553 
% 
Reduction 
 ↓90.45 ↓10.83 ↓93.0  ↓47.37 ↓8.27 ↓90.0 
 
Group I (susceptible group): mice infected with PZQ susceptible cercariaee; Ia: non 
treated; Ib: PZQ treated; Ic: niosomes nanoparticles treated; Id:  PZQ niosomes 
nanoparticles treated. 
Group II (group with reduced sensitivity to PZQ): mice infected with cercariae with 
reduced sensitivity to PZQ; IIa: non treated; IIb: PZQ treated; IIc: niosomes 




% Reduction: Percentage reduction between each subgroup and the control subgroup 
P: Kruskal Wallis test, Significance between groups was done using Mann Whitney 
test. 
Pcontrol : p value for comparing between Control and each subgroup 
p1: p value for comparing between Ib and Ic 
p2: p value for comparing between Ib and Id 
p3: p value for comparing between Ic and Id    
p4: p value for comparing between IIb and IIc 
p5: p value for comparing between IIb and IId  
p6: p value for comparing between IIc and IId 
p7: p value for comparing between Ia and IIa 
p8: p value for comparing between Ib and IIb 
p9: p value for comparing between Ic and IIc 




Table 2 Hepatic and intestinal tissue egg counts (102) per gram of tissue among the 
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p7= 0.016*, p8= 0.025*, p9= 0.078, p10<0.001* 
% reduction  ↓89.54 ↓29.67 ↓94.59  ↓65.02 ↓28.17 ↓97.68 
Intestinal egg 
count 
        





























p7= 0.037*, p8= 0.010*, p9= 1.000, p10<0.001* 
% reduction  ↓85.12 ↓37.02 ↓89.0  ↓40.56 ↓3.87 ↓98.56 
 
Group I (susceptible group): mice infected with PZQ susceptible cercariaee; Ia: non 
treated; Ib: PZQ treated; Ic: niosomes nanoparticles treated; Id:  PZQ niosomes 
nanoparticles treated. 
Group with reduced sensitivity to PZQ (group II): mice infected with cercariae with 
reduced sensitivity to PZQ; IIa: non treated; IIb: PZQ treated; IIc: niosomes 
nanoparticles treat ed; IId:  PZQ niosomes nanoparticles treated. 
 
% Reduction: Percentage reduction between each subgroup and the control subgroup 
P: Kruskal Wallis test, Significance between groups was done using Mann Whitney 
test. 
Pcontrol : p value for comparing between Control and each subgroup 
p1: p value for comparing between Ib and Ic 
p2: p value for comparing between Ib and Id 
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p3: p value for comparing between Ic and Id  
p4: p value for comparing between IIb and IIc 
p5: p value for comparing between IIb and IId 
p6: p value for comparing between IIc and IId 
p7: p value for comparing between Ia and IIa 
p8: p value for comparing between Ib and IIb 
p9: p value for comparing between Ic and IIc 
p10: p value for comparing between Id and IId 










Group I (Susceptible group) 
Group II (Group with reduced 
sensitivity to PZQ) 
Ia 
(Control) 
Ib Ic Id IIa 
(Control) 
IIb IIc IId 























Pcontrol  0.054 0.261 <0.001*  0.748 0.337 0.024* 






Sig. bet. Groups p7=0.337, p8=0.520, p9=0.128, p10=0.027* 




















0.0 ±  
0.0 
Pcontrol  0.004* 0.469 <0.001*  0.045* 0.520 0.002* 






Sig. bet. Groups p7=0.520, p8=0.200, p9=0.335, p10<0.001* 
























Pcontrol  0.004* 0.090 <0.001*  0.043* 0.168 0.004* 






Sig. bet. Groups p7=0.049*, p8=0.423, p9=0.257, p10=0.123 
 
Group I (susceptible group): mice infected with PZQ susceptible cercariae; Ia: non 
treated; Ib: PZQ treated; Ic: niosomes nanoparticles treated; Id:  PZQ niosomes 
nanoparticles treated. 
Group II (Group with reduced sensitivity to PZQ): mice infected with cercariae with 
reduced sensitivity to PZQ; IIa: non treated; IIb: PZQ treated; IIc: niosomes 
nanoparticles treated; IId:  PZQ niosomes nanoparticles treated. 
 
% Reduction: Percentage reduction between each subgroup and the control subgroup 
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P: Kruskal Wallis test, Significance between groups was done using Mann Whitney 
test. 
Pcontrol: p value for comparing between Control and each subgroup 
p1: p value for comparing between Ib and Ic 
p2: p value for comparing between Ib and Id 
p3: p value for comparing between Ic and Id    
p4: p value for comparing between IIb and IIc 
p5: p value for comparing between IIb and IId  
p6: p value for comparing between IIc and IId 
p7: p value for comparing between Ia and IIa 
p8: p value for comparing between Ib and IIb 
p9: p value for comparing between Ic and IIc 
p10: p value for comparing between Id and IId 
*: Statistically significant at P ≤ 0.05 
 
